New research shows risankizumab delivers long-term psoriasis control, with OCT revealing reduced subclinical inflammation.
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced ...
Galea, H. , Perry, M. and Jones, P. (2026) Characterising Irritable Bowel Syndrome: An Exploratory Cross-Sectional Study .
Exploratory NordVPN study reveals stolen airline and hotel loyalty accounts traded on dark web forums. Insights ...
MaaT Pharma Announces First Patient Randomized in IMMUNOLIFE Phase 2 Study Sponsored by Gustave Roussy, in Advanced NSCLC ...
IMMUNOLIFE, a Phase 2 randomized exploratory study, will evaluate the potential of MaaT033 in combination with Cemiplimab versus Best Investigator Choice (i.e.: second line) in enhancing disease ...
In a recent study published in the journal Mindfulness, researchers examine the prevalence and effects of emergent phenomena (EP), their forms, the balance of positive and negative repercussions, and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results